Table 3.
Clinical, patient-reported and cost measurements reported in included studies
| Study (first author*) | Measurements | ||
|---|---|---|---|
| Clinical | Patient-reported | Cost | |
| Treatment-related observational studies | |||
| Driessen 2008[68] | PASI | - | - |
| Fortune 2003[6] | Time taken to achieve clearance of psoriasis | Psychological distress, alcohol intake, HADS | - |
| Lecha 2005[70] | psoriasis severity and area, global efficacy and tolerability | Patients' satisfaction [tools not described]. | - |
| Naldi 2008[71] | PASI, BMI | - | - |
| Paul 2003[72] | Malignancies | - | - |
| Wahl 2005[73] | SPASI | SF-36, one item on QOL and one assessment of self-acceptance | - |
| Heiberg 2008[74] | DAS-28 | HAQ; SF-36; SF-6D (utility) | - |
| Kristensen 2008[76] | DAS-28, erythrocyte sedimentation rate and C-reactive protein | EQ-5D (utility) HAQ, VAS-pain, VAS-global, global evaluation | - |
| Sparado 1997[80] | Type of therapy; drug continuation; Number of painful and swollen joints; remission | - | - |
| Saad 2009[81] | Drug persistence; DAS-28 | HAQ adapted for UK use and SF-36 | - |
| Non-treatment related observational studies | |||
| Carrascosa 2006[84] | PASI | Direct, indirect | |
| Colombo 2008[11] | PASI | SF-36, DLQI | Direct, indirect |
| Schmid-ott 2005[85] | PASI, SPASI | QES | - |
| Husted 2007[2] | Mortality; PASI; Duration of morning stiffness, and total numbers of actively inflamed joints; incidence of CVD; malignancies | HAQ | - |
| Kane 2003[95] | PASI, Ritchie Articular Index, EULAR swollen joint count, joint stiffness on waking. | HAQ | - |
| Lindqvist 2008[97] | 66/68 joint counts, PASI, physician's global assessment of joint disease activity, and subclassification; remission | VAS, HAQ, SF-36 | - |
*Primary paper for the study or the most recent analysis of the cohort.
PASI, psoriasis area and severity index. HADS, hospital anxiety and depression scale. DAS-28, disease activity score-28. HAQ, health assessment questionnaire. VAS, visual analogue scale. BMI, body mass index. SPASI, self-administered PASI. QOL, quality of life, DMARDs, disease-modifying anti-rheumatic drugs. DLQI, dermatology life quality index. QES, questionnaire on experiences with skin complaints.